Shanghai-based WuXi PharmaTech ($WX) said its subsidiary WuXi NextCODE Genomics has joined with U.S.-based DNAnexus to offer a wider range of genomics services, including cloud-based services that are billed as the first unified global platform for precision medicine research, according to a press release on Wednesday.
 |
| WuXi PharmaTech CEO Ge Li |
WuXi said that a single platform provides a sequence data analysis suite that has analyzed more genomes than any other and that brings cloud-based genomics to China and Chinese genomics to the world.
"This strategic investment and partnership bring together the world's best technologies to enable any company or institution to leverage the full power of genomics and our R&D capabilities at any time, from anywhere," said Ge Li, CEO of WuXi PharmaTech.
The companies will also provide and host the same platform and capabilities within China, in full compliance with local regulations, according to the release. Users will be able to use their genomic data seamlessly in tandem with the open-access capability and technology platform that WuXi offers to the global pharmaceutical, biopharmaceutical and medical device industry.
NYSE-listed WuXi PharmaTech has flagged how it would spend recent borrowings of $165 million in an aggressive plan of building and financial targets in 2015. The company handles pharmaceutical, biopharmaceutical and medical device operations in China and the United States.
- here's the WuXi release